Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 147 points (1.0%) at 15,587 as of Thursday, Feb. 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,311 issues advancing vs. 626 declining with 152 unchanged. The Health Care sector currently sits up 0.8% versus the S&P 500, which is up 1.0%. On the negative front, top decliners within the sector include Perrigo Company ( PRGO), down 3.5%, AstraZeneca ( AZN), down 2.1%, Sanofi ( SNY), down 1.8% and Teva Pharmaceutical Industries ( TEVA), down 1.6%. Top gainers within the sector include Smith & Nephew ( SNN), up 2.2%, Grifols ( GRFS), up 2.1%, Regeneron Pharmaceuticals ( REGN), up 2.0%, Biogen Idec ( BIIB), up 1.9% and Shire ( SHPG), up 1.8%. TheStreet would like to highlight 3 stocks pushing the sector lower today: 3. Alere ( ALR) is one of the companies pushing the Health Care sector lower today. As of noon trading, Alere is down $2.52 (-6.8%) to $34.41 on heavy volume. Thus far, 1.7 million shares of Alere exchanged hands as compared to its average daily volume of 579,800 shares. The stock has ranged in price between $33.70-$37.52 after having opened the day at $37.17 as compared to the previous trading day's close of $36.93. Alere Inc. provides diagnostics and services for cardiology, infectious disease, toxicology, and diabetes in the United States and internationally. The company operates in three segments: Professional Diagnostics, Health Information Solutions, and Consumer Diagnostics. Alere has a market cap of $3.0 billion and is part of the health services industry. Shares are up 2.0% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts that rate Alere a buy, 1 analyst rates it a sell, and 3 rate it a hold. TheStreet Ratings rates Alere as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, generally higher debt management risk and weak operating cash flow. Get the full Alere Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.